ArticleAntimicrobial agents and chemotherapy2020
Lysophosphatidylcholine Potentiates Antibacterial Activity of Polymyxin B.
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Phytochemical Characterization and Antimicrobial Properties of a Hydroalcoholic Extract ofAntibiotics (Basel, Switzerland) · 2026Article
- Competition between resident rhizosphere bacteria enhances phytopathogen suppression via emergent antagonism.The ISME journal · 2026Article
- Article
- Cell Membrane Remodeling Mediates Polymyxin B Resistance inFrontiers in microbiology · 2022Article
- Effects of Lysophosphatidylcholine on Jejuna Morphology and Its Potential Mechanism.Frontiers in veterinary science · 2022Article
- Efficacy of Lysophosphatidylcholine as Direct Treatment in Combination with Colistin againstAntibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymyxin B, used to treat infections caused by antibiotic-resistant Gram-negative bacteria, produces nephrotoxicity at its current dosage. We show that a combination of nonbactericidal concentration of this drug and lysophosphatidylcholine (LPC) potently inhibits growth of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.